Results of treatment with lenalidomide
| Outcome . | Lenalidomide (n = 32) . |
|---|---|
| Best response | |
| PR | 9 (28%) |
| SD | 17 (53%) |
| PD | 3 (9%) |
| Not evaluated* | 3 (9%) |
| Response duration (mo)† | |
| Median (95% CI) | 10 (1.1-11.0) |
| Progression-free survival (mo) | |
| Median (95% CI) | 8 (3.7-26.1) |
| OS (mo) | |
| Median (95% CI) | 43 (21.6-45.2) |
| Status at last follow-up | |
| Alive | 14 (44%) |
| Dead | 18 (56%) |
| Outcome . | Lenalidomide (n = 32) . |
|---|---|
| Best response | |
| PR | 9 (28%) |
| SD | 17 (53%) |
| PD | 3 (9%) |
| Not evaluated* | 3 (9%) |
| Response duration (mo)† | |
| Median (95% CI) | 10 (1.1-11.0) |
| Progression-free survival (mo) | |
| Median (95% CI) | 8 (3.7-26.1) |
| OS (mo) | |
| Median (95% CI) | 43 (21.6-45.2) |
| Status at last follow-up | |
| Alive | 14 (44%) |
| Dead | 18 (56%) |